RecallRadar

FDA Drug recall D-0559-2024

Cefixime for Oral Suspension USP 200 mg/5 mL (50 mL Pack size), Powder for oral suspension, Rx only, Manufactured for: Lupin Pharmaceutical…

On 2024-06-26 the FDA classified a Class II recall of Cefixime for Oral Suspension USP 200 mg/5 mL (50 mL Pack size), Powder for oral suspension, Rx only, Manufactured for: Lupin Pharmaceutical… by Lupin Pharmaceuticals, citing failed Content Uniformity Specifications.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0559-2024
ClassificationClass II
Statusterminated
Initiated2024-05-30
Published2024-06-26
Last updated2026-09-13 11:52 UTC
CompanyLupin Pharmaceuticals
DistributionUS

Product

Cefixime for Oral Suspension USP 200 mg/5 mL (50 mL Pack size), Powder for oral suspension, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore Maryland, Manufactured by: Lupin Limited, Mandideep, India NDC 68180-407-03

Reason

Failed Content Uniformity Specifications

Identifiers

ndc68180-405-01
ndc68180-407-03
ndc68180-407-04
ndc68180-416-08
ndc68180-416-11
ndc68180-423-11
ndc68180-423-08
code_infoLot F201519, Expiry: November 2024

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0559-2024%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.